跳至主要内容
临床试验/CTRI/2025/07/090769
CTRI/2025/07/090769尚未招募2/3 期

A Randomised Controlled Clinical Trial Of Medhya Effect Of Shalaparni (Desmodium gangeticum (L.) DC) Churna With Ashwagandha (Withania somnifera (L.) Dunal) Churna In Anavasthita Chitta In Perspective Of Generalized Anxiety Disorder in Adult Population.

Vd. Shivangi Bodas1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2025年8月1日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
46
试验地点
1
主要终点
Decrease in the symptoms of anxiety and reduction of score (HAM-A Scale) by 50% or more

研究概览

简要总结

The primary objective of this open-labelled, randomized controlled clinical trial is to assess the effect of Shalaparni (Desmodium gangeticum (L.) DC) churna with respect to Ashwagandha churna for the management of Anavasthita Chitta  in perspective of Generalized Anxiety Disorder.

The secondary objectives are:

  1. To collect a genuine sample of Shalaparni (Desmodium gangeticum (L.) DC) and to study its pharmacognostic and physicochemical properties.
  2. To study the cultivation practices of Shalaparni and to cultivate it as per feasibility.

A total of 46 participants between the ages of 20 and 40 years, having moderate to severe anxiety as per the GAD-7 scale, will be selected for the study. They will be randomly allocated into two groups. Participants in Group A will receive the study drug, i.e., Shalaparni churna, and participants in Group B will receive the control drug, i.e., Ashwagandha churna.

Assessment will be carried out using the Hamilton Anxiety Rating Scale (HAM-A) at the beginning of the study. Participants will then receive the respective drugs, to be taken for a duration of two months. Reassessment using the HAM-A scale will be conducted at the end of two months. An improvement of 50% or more in the HAM-A score will be considered significant.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
None

入排标准

年龄范围
20.00 Year(s) 至 40.00 Year(s)(—)
性别
All

入选标准

  • Participants will be selected irrespective of gender with age between 20-40 years, fulfilling criteria for generalized anxiety disorder given in the Diagnostic and Statistical Manual of Mental Disorders.

排除标准

  • Participants with known case of any serious illness (cardiac, hepatic, renal disease, respiratory disorder, cancer etc.) Participants with known case of Mental retardation or having any other psychiatric treatment Pregnant or lactating woman.

结局指标

主要结局

Decrease in the symptoms of anxiety and reduction of score (HAM-A Scale) by 50% or more

时间窗: Every 15 days for 2 months

次要结局

  • Evaluating any other effect of shalaparni clinically(2 months)

研究者

发起方
Vd. Shivangi Bodas
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Vd Shivangi Vinay Bodas

Tilak Ayurved Mahavidyalaya, Pune

研究点 (1)

Loading locations...

相似试验